These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31398032)

  • 1. A Qualified Success: Discovery of a New Series of ATAD2 Bromodomain Inhibitors with a Novel Binding Mode Using High-Throughput Screening and Hit Qualification.
    Bamborough P; Chung CW; Demont EH; Bridges AM; Craggs PD; Dixon DP; Francis P; Furze RC; Grandi P; Jones EJ; Karamshi B; Locke K; Lucas SCC; Michon AM; Mitchell DJ; Pogány P; Prinjha RK; Rau C; Roa AM; Roberts AD; Sheppard RJ; Watson RJ
    J Med Chem; 2019 Aug; 62(16):7506-7525. PubMed ID: 31398032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach.
    Miller DC; Martin MP; Adhikari S; Brennan A; Endicott JA; Golding BT; Hardcastle IR; Heptinstall A; Hobson S; Jennings C; Molyneux L; Ng Y; Wedge SR; Noble MEM; Cano C
    Org Biomol Chem; 2018 Mar; 16(11):1843-1850. PubMed ID: 29469144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aiming to Miss a Moving Target: Bromo and Extra Terminal Domain (BET) Selectivity in Constrained ATAD2 Inhibitors.
    Bamborough P; Chung CW; Furze RC; Grandi P; Michon AM; Watson RJ; Mitchell DJ; Barnett H; Prinjha RK; Rau C; Sheppard RJ; Werner T; Demont EH
    J Med Chem; 2018 Sep; 61(18):8321-8336. PubMed ID: 30226378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a Potent and Selective ATAD2 Bromodomain Inhibitor with Antiproliferative Activity in Breast Cancer Models.
    Winter-Holt JJ; Bardelle C; Chiarparin E; Dale IL; Davey PRJ; Davies NL; Denz C; Fillery SM; Guérot CM; Han F; Hughes SJ; Kulkarni M; Liu Z; Milbradt A; Moss TA; Niu H; Patel J; Rabow AA; Schimpl M; Shi J; Sun D; Yang D; Guichard S
    J Med Chem; 2022 Feb; 65(4):3306-3331. PubMed ID: 35133824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode.
    Lucas SCC; Atkinson SJ; Bamborough P; Barnett H; Chung CW; Gordon L; Mitchell DJ; Phillipou A; Prinjha RK; Sheppard RJ; Tomkinson NCO; Watson RJ; Demont EH
    J Med Chem; 2020 May; 63(10):5212-5241. PubMed ID: 32321240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action.
    Fernández-Montalván AE; Berger M; Kuropka B; Koo SJ; Badock V; Weiske J; Puetter V; Holton SJ; Stöckigt D; Ter Laak A; Centrella PA; Clark MA; Dumelin CE; Sigel EA; Soutter HH; Troast DM; Zhang Y; Cuozzo JW; Keefe AD; Roche D; Rodeschini V; Chaikuad A; Díaz-Sáez L; Bennett JM; Fedorov O; Huber KVM; Hübner J; Weinmann H; Hartung IV; Gorjánácz M
    ACS Chem Biol; 2017 Nov; 12(11):2730-2736. PubMed ID: 29043777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel ATAD2 bromodomain inhibitors that trigger apoptosis and autophagy in breast cells by structure-based virtual screening.
    Yao D; Zhang J; Wang J; Pan D; He Z
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):713-725. PubMed ID: 32174193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATAD2 in cancer: a pharmacologically challenging but tractable target.
    Hussain M; Zhou Y; Song Y; Hameed HMA; Jiang H; Tu Y; Zhang J
    Expert Opin Ther Targets; 2018 Jan; 22(1):85-96. PubMed ID: 29148850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The identification of new ATAD2 bromodomain inhibitors: the application of combined ligand and structure-based virtual screening.
    Sepehri B; Ghavami R
    SAR QSAR Environ Res; 2017 Dec; 28(12):957-971. PubMed ID: 29191061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disulfide bridge formation influences ligand recognition by the ATAD2 bromodomain.
    Gay JC; Eckenroth BE; Evans CM; Langini C; Carlson S; Lloyd JT; Caflisch A; Glass KC
    Proteins; 2019 Feb; 87(2):157-167. PubMed ID: 30520161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Demonstration of the Biological Relevance of sp
    Foley DJ; Craven PGE; Collins PM; Doveston RG; Aimon A; Talon R; Churcher I; von Delft F; Marsden SP; Nelson A
    Chemistry; 2017 Oct; 23(60):15227-15232. PubMed ID: 28983993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coordination of Di-Acetylated Histone Ligands by the ATAD2 Bromodomain.
    Evans CM; Phillips M; Malone KL; Tonelli M; Cornilescu G; Cornilescu C; Holton SJ; Gorjánácz M; Wang L; Carlson S; Gay JC; Nix JC; Demeler B; Markley JL; Glass KC
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening.
    Paricharak S; Méndez-Lucio O; Chavan Ravindranath A; Bender A; IJzerman AP; van Westen GJP
    Brief Bioinform; 2018 Mar; 19(2):277-285. PubMed ID: 27789427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hot-Spotting with Thermal Scanning: A Ligand- and Structure-Independent Assessment of Target Ligandability.
    Chilton M; Clennell B; Edfeldt F; Geschwindner S
    J Med Chem; 2017 Jun; 60(12):4923-4931. PubMed ID: 28537726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hit-to-Lead: Hit Validation and Assessment.
    Hevener KE; Pesavento R; Ren J; Lee H; Ratia K; Johnson ME
    Methods Enzymol; 2018; 610():265-309. PubMed ID: 30390802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Insights into the Recognition of Mono- and Diacetylated Histones by the ATAD2B Bromodomain.
    Lloyd JT; McLaughlin K; Lubula MY; Gay JC; Dest A; Gao C; Phillips M; Tonelli M; Cornilescu G; Marunde MR; Evans CM; Boyson SP; Carlson S; Keogh MC; Markley JL; Frietze S; Glass KC
    J Med Chem; 2020 Nov; 63(21):12799-12813. PubMed ID: 33084328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Guide to Run Affinity Screens Using Differential Scanning Fluorimetry and Surface Plasmon Resonance Assays.
    Bergsdorf C; Wright SK
    Methods Enzymol; 2018; 610():135-165. PubMed ID: 30390797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
    Romero FA; Taylor AM; Crawford TD; Tsui V; Côté A; Magnuson S
    J Med Chem; 2016 Feb; 59(4):1271-98. PubMed ID: 26572217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hit finding: towards 'smarter' approaches.
    Langer T; Hoffmann R; Bryant S; Lesur B
    Curr Opin Pharmacol; 2009 Oct; 9(5):589-93. PubMed ID: 19576852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMR-based platform for fragment-based lead discovery used in screening BRD4-targeted compounds.
    Yu JL; Chen TT; Zhou C; Lian FL; Tang XL; Wen Y; Shen JK; Xu YC; Xiong B; Zhang NX
    Acta Pharmacol Sin; 2016 Jul; 37(7):984-93. PubMed ID: 27238211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.